title: [Perceptual gap between oncologists/oncology nurses and patients in the management and impact of chemotherapy/radiotherapy-induced nausea and vomiting: French results of the GAP survey].
abstract: BACKGROUND
  Despite progress in the treatment of chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV), their management remains insufficient.
  
  
  METHODS
  In order to evaluate the incidence and impact of CINV/RINV on the quality of life perceived by patients and estimated by clinicians, a declarative, cross-sectional survey was conducted in France through an online questionnaire.
  
  
  RESULTS
  This survey included 187 participants: 75 oncologists, 35 oncology nurses and 77 patients. Clinicians over-estimated the incidence of CINV/RINV, but underestimated their impact on the quality of life of patients. The sub-optimal prescription of anti-emetic treatments was more prominent when the therapy administered had low or medium emetogenic potential. Only 30% of patients rated their nausea and vomiting as controlled from the start. A major proportion of patients (68%) declared poor compliance with their anti-emetic regimen. The acceptance of CINV/RINV as normal side effects of the chemotherapy/radiotherapy (51%) led the patients not to report them, thus limiting their active management. The number of drugs to absorb, and the fear that the action of swallowing the pill would induce nausea or vomiting were also quoted by the patients as compliance-limiting factors.
  
  
  CONCLUSIONS
  The perceptual gap between clinicians and patients regarding the incidence and impact of CINV/RINV contributes to a sub-optimal level of anti-emetic cover and control. The anti-emetic regimen needs to be regularly assessed and adapted to the patient in order to improve CINV/RINV management.
authors.affiliation: Hôpital européen Georges-Pompidou, unité d'hospitalisation en soins de support en oncologie, 20, rue Leblanc, 75908 Paris cedex 15, France. Electronic address: sophie.morin@aphp.fr.
authors.forename: Sophie
authors.initials: S
authors.lastname: Morin
authors.affiliation: Norgine Pharma, 2, rue Jacques-Daguerre, 92565 Rueil-Malmaison cedex, France.
authors.forename: Irina
authors.initials: I
authors.lastname: Leurs
authors.affiliation: Norgine Pharma, 2, rue Jacques-Daguerre, 92565 Rueil-Malmaison cedex, France.
authors.forename: Marie-Noëlle
authors.initials: MN
authors.lastname: Bousquet
authors.affiliation: Hôpital européen Georges-Pompidou, unité d'hospitalisation en soins de support en oncologie, 20, rue Leblanc, 75908 Paris cedex 15, France.
authors.forename: Florian
authors.initials: F
authors.lastname: Scotté
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D005060:Europe; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D009325:Nausea / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D000072103:Oncologists; D009859:Oncology Nursing; D010349:Patient Compliance / Q000523:psychology / Q000706:statistics & numerical data; D011788:Quality of Life; D011878:Radiotherapy / Q000009:adverse effects*; D011795:Surveys and Questionnaires; D014839:Vomiting / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents
keywords: Anti-emetic; Antiémétique; Chemotherapy/radiotherapy-induced nausea and vomiting; Décalage de perception; Impact; Incidence; Nausées et vomissements chimio/radio-induits; Perceptual gap; Quality of life; Qualité de vie